BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 28980742)

  • 1. Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: contribution to the epithelial-stromal interaction balance.
    Nogueira Pangrazi E; da Silva RF; Kido LA; Montico F; Cagnon VHA
    Cell Biol Int; 2018 Feb; 42(2):153-168. PubMed ID: 28980742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
    da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
    J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
    Mateus PAM; Kido LA; Silva RS; Cagnon VHA; Montico F
    Prostate; 2019 Apr; 79(5):515-535. PubMed ID: 30585351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
    da Silva RF; Banzato TP; Alves LF; Carvalho JE; Agarwal R; Cagnon VHA
    Cell Tissue Res; 2020 Feb; 379(2):407-420. PubMed ID: 31473819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib effects on delaying cancer progression and decreasing COX-2 and IL-17 in the prostate anterior lobe in TRAMP mice.
    Alves LF; da Silva RF; Cagnon VHA
    Tissue Cell; 2018 Feb; 50():96-103. PubMed ID: 29429524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy.
    Montico F; Lamas CA; Rossetto IMU; Baseggio AM; Cagnon VHA
    J Mol Histol; 2023 Aug; 54(4):379-403. PubMed ID: 37335420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
    Kido LA; Montico F; Sauce R; Macedo AB; Minatel E; Costa DB; Carvalho JE; Pilli RA; Cagnon VH
    Endocr Relat Cancer; 2016 Apr; 23(4):235-50. PubMed ID: 26772819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Montico F; Kido LA; Hetzl AC; Cagnon VH
    Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamin treatments in TRAMP mice.
    Silva RS; Kido LA; Montico F; Vendramini-Costa DB; Pilli RA; Cagnon VHA
    Cell Biol Int; 2018 Aug; 42(8):1006-1020. PubMed ID: 29603508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive stroma in the prostate during late life: The role of microvasculature and antiangiogenic therapy influences.
    Montico F; Kido LA; San Martin R; Rowley DR; Cagnon VH
    Prostate; 2015 Oct; 75(14):1643-61. PubMed ID: 26184673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
    Singh RP; Raina K; Sharma G; Agarwal R
    Clin Cancer Res; 2008 Dec; 14(23):7773-80. PubMed ID: 19047104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.
    Ronca R; Alessi P; Coltrini D; Di Salle E; Giacomini A; Leali D; Corsini M; Belleri M; Tobia C; Garlanda C; Bonomi E; Tardanico R; Vermi W; Presta M
    J Pathol; 2013 Jun; 230(2):228-38. PubMed ID: 23424081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzyl Isothiocyanate Inhibits Prostate Cancer Development in the Transgenic Adenocarcinoma Mouse Prostate (TRAMP) Model, Which Is Associated with the Induction of Cell Cycle G1 Arrest.
    Cho HJ; Lim DY; Kwon GT; Kim JH; Huang Z; Song H; Oh YS; Kang YH; Lee KW; Dong Z; Park JH
    Int J Mol Sci; 2016 Feb; 17(2):264. PubMed ID: 26907265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators.
    da Silva RF; Dhar D; Raina K; Kumar D; Kant R; Cagnon VHA; Agarwal C; Agarwal R
    Sci Rep; 2018 Jun; 8(1):9540. PubMed ID: 29934570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High animal fat intake enhances prostate cancer progression and reduces glutathione peroxidase 3 expression in early stages of TRAMP mice.
    Chang SN; Han J; Abdelkader TS; Kim TH; Lee JM; Song J; Kim KS; Park JH; Park JH
    Prostate; 2014 Sep; 74(13):1266-77. PubMed ID: 25053105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.
    Harper CE; Patel BB; Wang J; Eltoum IA; Lamartiniere CA
    Prostate; 2007 Oct; 67(14):1576-89. PubMed ID: 17705241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit.
    Wang L; Bonorden MJ; Li GX; Lee HJ; Hu H; Zhang Y; Liao JD; Cleary MP; Lü J
    Cancer Prev Res (Phila); 2009 May; 2(5):484-95. PubMed ID: 19401524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential tempol effects in prostatic cancer: angiogenesis and short- and long-term treatments.
    Santos FR; Rossetto IMU; Montico F; de Almeida Lamas C; Cagnon VHA
    J Mol Histol; 2024 Jun; 55(3):253-264. PubMed ID: 38551737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
    Narayanan BA; Narayanan NK; Pittman B; Reddy BS
    Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.
    Chung AC; Zhou S; Liao L; Tien JC; Greenberg NM; Xu J
    Cancer Res; 2007 Jun; 67(12):5965-75. PubMed ID: 17575167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.